uniQure (NASDAQ:QURE) Price Target Raised to $70.00 at HC Wainwright

uniQure (NASDAQ:QURE) had its price objective hoisted by analysts at HC Wainwright from $25.00 to $70.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 346.71% from the company’s previous close.

Other analysts have also issued research reports about the company. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $20.00 to $52.00 in a report on Tuesday, December 10th. Stifel Nicolaus boosted their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, December 16th. The Goldman Sachs Group lifted their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Finally, Leerink Partners boosted their price target on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, uniQure has a consensus rating of “Moderate Buy” and an average target price of $40.00.

uniQure Trading Down 1.0 %

NASDAQ QURE opened at $15.67 on Monday. The stock has a market capitalization of $763.76 million, a price-to-earnings ratio of -3.16 and a beta of 0.41. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The stock’s 50 day moving average price is $12.93 and its two-hundred day moving average price is $8.74. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.12) by $0.21. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. The business had revenue of $2.29 million during the quarter, compared to analysts’ expectations of $2.73 million. As a group, analysts anticipate that uniQure will post -3.74 earnings per share for the current fiscal year.

Insider Activity

In other uniQure news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now directly owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.74% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. RTW Investments LP acquired a new position in uniQure during the 3rd quarter worth approximately $49,000. China Universal Asset Management Co. Ltd. increased its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new position in uniQure in the third quarter valued at about $53,000. Quarry LP acquired a new stake in shares of uniQure during the third quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.